Morphotek Announces the Appointment of Rodney Dausch as Vice President and Chief Financial Officer

Morphotek Inc. announced today the appointment of Rodney Dausch as Vice President and Chief Financial Officer. Mr. Dausch has over 30 years of experience in financial and operations management, most recently as Executive Vice President and Chief Operating Officer for a publicly held biopharmaceutical company, where he also led its successful initial and follow-on public offerings as Chief Financial Officer.

"Rod brings with him an outstanding record of achievements in senior finance and administration positions at both private and publicly held biotechnology companies," said Nicholas C. Nicolaides, President and Chief Executive Officer. "His extensive operational skills and business networks will bring additional resources and leadership to Morphotek's senior management team in helping the Company strategically coordinate its growth as well as execute its near and long term objectives. I am delighted to have him join the Morphotek team."

Mr. Dausch received his B.S. degree from Loyola College and was a Certified Public Accountant. He began his career with Ernst & Young before moving into the biotechnology sector.

Morphotek (www.morphotek.com) is a biotechnology company focused on the generation of proprietary organisms for product development using a patented platform technology that can enhance the natural process of genetic evolution within a targeted host. The technology has been successfully applied to microbes, plants, and mammals to yield genetically diverse offspring that are suitable for pharmaceutical and agricultural product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.

Back to 2002 News Archive